Screening for Anxiety and Depressive Symptoms in Type 2 Diabetes Using Patient-Reported Outcome Measures: Comparative Performance of the EQ-5D-5L and SF-12v2
Fatima Al Sayah, Arto Ohinmaa, Jeffrey A. Johnson
MDM Policy and Practice 2018 (in press)
Anxiety and depressive symptoms are highly prevalent in chronic disease patients, including those with type 2 diabetes. These symptoms, often undiagnosed and untreated, adversely impact diabetes management and outcomes.
In this study, Al Sayah and colleagues examined the performance of two of the most commonly used patient-reported outcome (PRO)measures of health-related quality of life (EQ-5D-5L and the SF-12 v.2) in screening for anxiety and depressive symptoms in type 2 diabetes patients in
The researchers found that the EQ-5D-5L and the SF-12 to be suitable tools for screening for anxiety and depressive symptoms in adults with type 2 diabetes. The anxiety/depression dimension of the EQ-5D and the MCS score of the SF-12 had the best performance in screening for these symptoms.
You can read the full article here: https://journals.sagepub.com/doi/full/10.1177/2381468318799361
For any questions or comments, please do not hesitate to contact us at email@example.com